Corbus Pharmaceuticals Holdings, Inc.

CRBP

US21833P3010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
50.31 ^USD	+1.31%		+11.18%	+732.95%

07-01	Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Comp Value Index	CI
07-01	Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Completeness Index	CI

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000 Growth Index

July 30, 2024

Latest news about Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Comp Value Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Completeness Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000 Value Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000E Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000 Growth Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2500 Value Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000E Growth Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Growth Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Dynamic Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2500 Growth Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Comp Growth Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2500 Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000 Index	06-30	CI
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 3000E Value Index	06-30	CI
B. Riley Initiates Coverage on Corbus Pharmaceuticals With Buy Rating, $85 Price Target	06-26	MT
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to S&P Biotechnology Select Industry Index	06-23	CI
Transcript : Corbus Pharmaceuticals Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:40 PM	06-12
RBC Raises Price Target on Corbus Pharmaceuticals Holdings to $82 From $77, Maintains Outperform, Speculative Risk	06-11	MT
Corbus Pharmaceuticals Reaches 2-Year High After Drug Results	06-03	DJ
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $80 From $60, Maintains Outperform Rating	06-03	MT
Corbus Pharmaceuticals Presents Positive Clinical Update on SYS6002 (CRB-701) at ASCO Conference	06-01	CI
RBC Initiates Corbus Pharmaceuticals Holdings at Outperform With Speculative Risk Qualifier, $77 Price Target	05-13	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $60 From $58, Maintains Outperform Rating	05-08	MT

Chart Corbus Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Corbus Pharmaceuticals Holdings, Inc.

More charts

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFÎ² expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

50.31 USD

Average target price

80.75 USD

Spread / Average Target

+60.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CORBUS PHARMACEUTICALS HOLDINGS, INC.	+732.95%	538M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs